New platform technologies for viral and therapeutic evolution assays

Ended Definitive Contract Awarded Last action

Contract number
140D6318C0006
Awardee
Awarding agency
Obligated
$3,007,558

Award facts

Opportunity
  • DODSBIR171 Solicitation number
Contract value 100% obligated
$3,007,557.97 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
Defense Advanced Research Projects Agency Department of Defense
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 12 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Brooklyn, NY 11205, USA
Research
SBIR Program Phase II Action
Legislative mandates
  • Other statutory authority

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00010 -$0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Funding Only Action P00007 $1,499,998
Other Administrative Action P00006 $0
Supplemental Agreement for work within scope P00005 $0
Supplemental Agreement for work within scope P00004 $0
Funding Only Action P00003 $499,186
Supplemental Agreement for work within scope P00002 $504,187
Other Administrative Action P00001 $0
Original award $504,187
Show all 11

About this award

This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also been awarded an Indefinite Delivery Vehicle (IDV) contract by DARPA, valued at up to $4,579,822, to develop and deliver therapeutic interfering particles against respiratory viral threats. Additionally, the company has received a $273,644 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance its antiviral research capabilities. These contract and grant awards highlight Autonomous Therapeutics' expertise in developing innovative medical countermeasures and rapid-response platforms for addressing viral infectious diseases, particularly those of concern to the defense sector.

Quick answers

Who was awarded contract 140D6318C0006?

140D6318C0006 was awarded to Autonomous Therapeutics Inc. by Interior Business Center (Office of Policy Management and Budget) on December 28, 2017.

How much is contract 140D6318C0006 worth?

The government has obligated $3,007,558 on 140D6318C0006.

Which agency awarded contract 140D6318C0006?

Interior Business Center (Office of Policy Management and Budget) awarded 140D6318C0006, with funding from Defense Advanced Research Projects Agency (Department of Defense).

Was contract 140D6318C0006 competed?

The extent of competition for 140D6318C0006 was full and open competition after exclusion of sources. The government received 12 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award